UBS lowered the firm’s price target on Iqvia (IQV) to $185 from $255 and keeps a Buy rating on the shares. The Technology & Analytics Solutions recovery is on track, but the firm sees incremental weakness in Research & Development Solutions, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $161 from $195 at Baird
- IQVIA Holdings: Strong Financial Performance and Promising Outlook Amidst Market Challenges
- Iqvia price target lowered to $165 from $170 at Barclays
- IQVIA Holdings Reports Strong Q1 2025 Results
- Resilience and Growth Prospects Drive Buy Rating for IQVIA Holdings Amid Industry Challenges